Original drug discount agreements for fluticasone/vilanterol 2026-07

Summary

The tender concerns discount agreements for original medicinal products containing the fluticasone/vilanterol active-substance combination. The participating health insurers intend to conclude agreements with all suitable pharmaceutical companies on uniform terms; individual negotiations will not be held and no contracting partner will receive exclusive rights. The agreement will run for up to 24 months from 1 October 2026 and will end no later than 30 September 2028, or earlier if the patent or market exclusivity expires. A suitable company may join the procedure at any time during the agreement period. The price, other detailed contractual terms and the evidence required from pharmaceutical companies must be checked in the participation and contract documents.